Cargando…

FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis

BACKGROUND: Tamoxifen is an important choice in endocrine therapy for patients with oestrogen receptor-positive (ER+) breast cancer, and disease progression-associated resistance to tamoxifen therapy is still challenging. Flap endonuclease-1 (FEN1) is used as a prognostic biomarker and is considered...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Lu, Shen, Ji-Ming, Qu, Jing-Lei, Song, Na, Che, Xiao-Fang, Hou, Ke-Zuo, Shi, Jing, Zhao, Lei, Shi, Sha, Liu, Yun-Peng, Qu, Xiu-Juan, Teng, Yue-E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940940/ https://www.ncbi.nlm.nih.gov/pubmed/33708885 http://dx.doi.org/10.21037/atm-20-3068

Ejemplares similares

Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance
por: Feng, Jing, et al.
Publicado: (2020)

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
por: Gao, Ang, et al.
Publicado: (2018)

Inhibition of FEN1 Increases Arsenic Trioxide-Induced ROS Accumulation and Cell Death: Novel Therapeutic Potential for Triple Negative Breast Cancer
por: Xin, Xing, et al.
Publicado: (2020)

The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance
por: Ferraiuolo, Rosa-Maria, et al.
Publicado: (2017)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Estrogen receptor variant ER‐α36 promotes tamoxifen agonist activity in glioblastoma cells
por: Qu, Chao, et al.
Publicado: (2019)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
por: Lv, Qing, et al.
Publicado: (2021)

A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastia
por: He, Weili, et al.
Publicado: (2023)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
por: Ouyang, Yan Xiu, et al.
Publicado: (2021)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
por: Meligova, Aggeliki K., et al.
Publicado: (2023)

Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER(+) breast cancer
por: Deng, Jing, et al.
Publicado: (2013)

ER-depletion lowering the 'hypothalamus-uterus-kidney' axis functions by perturbing the renal ERβ/Ptgds signalling pathway
por: Liu, Yan-Ru, et al.
Publicado: (2019)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021)

Biological and clinical significance of flap endonuclease-1 in triple-negative breast cancer: Support of metastasis and a poor prognosis
por: Xu, Lu, et al.
Publicado: (2020)

Tamoxifen-independent Cre-activity in SMMHC-CreER(T2) mice
por: Steffensen, L.B., et al.
Publicado: (2022)

Single-molecule characterization of Fen1 and Fen1/PCNA complexes acting on flap substrates
por: Craggs, Timothy D., et al.
Publicado: (2014)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

The FEN1 E359K germline mutation disrupts the FEN1-WRN interaction and FEN1 GEN activity, causing aneuploidy-associated cancers
por: Chung, Lin, et al.
Publicado: (2014)

Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer
por: Gu, Yu, et al.
Publicado: (2016)

Zika NS1–induced ER remodeling is essential for viral replication
por: Ci, Yali, et al.
Publicado: (2019)

LncRNA GNAS-AS1 facilitates ER(+) breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis
por: Liu, Shi-Qin, et al.
Publicado: (2020)

Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells.
por: Benson, J. R., et al.
Publicado: (1996)

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)

PACS2–TRPV1 axis is required for ER–mitochondrial tethering during ER stress and lung fibrosis
por: Knoell, Jessica, et al.
Publicado: (2022)

BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast
por: Millar, E K A, et al.
Publicado: (2009)

δEF1 Down-Regulates ER-α Expression and Confers Tamoxifen Resistance in Breast Cancer
por: Guo, Shaocong, et al.
Publicado: (2012)

Tamoxifen Inhibits ER-negative Breast Cancer Cell Invasion and Metastasis by Accelerating Twist1 Degradation
por: Ma, Gang, et al.
Publicado: (2015)

High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers
por: Ahlin, Cecilia, et al.
Publicado: (2017)

YAP inhibits ERα and ER(+) breast cancer growth by disrupting a TEAD-ERα signaling axis
por: Li, Xu, et al.
Publicado: (2022)

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
por: Gao, Tian, et al.
Publicado: (2014)

Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model
por: De Oliveira Andrade, Fabia, et al.
Publicado: (2019)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression
por: Li, Yuanyuan, et al.
Publicado: (2017)

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
por: Reese, Jordan M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8b9ggthn2r30crmsolg33pekf0